NHS: DRUGS
Nicholas Soames: To ask the Secretary of State for Health how much has been spent by NHS trusts in London on (a) anti-retroviral HIV drugs and (b) anti-cancer drugs in each of the last five years. [161942]
Norman Lamb, Minister of State for Care and Support: Expenditure by national health service trusts in London, as defined by the former London strategic health authority (SHA), is provided for both anti-retroviral HIV medicines and anti-cancer medicines.
London generally has a larger proportion of its medicines costs going through hospitals than other SHAs as patients from areas surrounding London are likely to travel to London hospitals for some treatments.
| £000 | |||
| Drug type | Year | Primary care cost(1) | Secondary care cost(2) |
| Anti-retroviral HIV(3) | 2008 | (4)321.0 | 175,398.3 |
| 2009 | 502.4 | 191,720.7 | |
| 2010 | 642.0 | 206,752.9 | |
| 2011 | 555.5 | 214,542.6 | |
| 2012 | 539.4 | 233,949.2 | |
| Anti-cancer(5) | 2008 | (4)17,299.8 | 112,677.5 |
| 2009 | 23,486.3 | 131,052.7 | |
| 2010 | 22,461.9 | 147,571.4 | |
| 2011 | 20,958.7 | 157,944.3 | |
| 2012 | (6)13,017.2 | 188,663.9 | |
| (1) Net ingredient cost. (2) Cost of medicines at NHS list price and not necessarily the price paid. (3) As classified within British National Formulary (BNF) section 5.3.1 ‘HIV infection’. (4) Information for 2008 primary care costs is only available for May-December 2008. (5) As classified within BNF section 8.1 ‘Cytotoxic drugs’, paragraph 8.2.3 ‘Anti-lymphocyte monoclonal antibodies’, paragraph 8.2.4 ‘Other immunomodulating drugs’ (Aldesleukin, Bacillus Calmette-Guerin (B.C.G.), Lenalidomide and Thalidomide (Immunomodulating) only), section 8.3 ‘Sex hormones and hormone antagonists in malignant disease’. (6) The main reason for the lower cost is the large reduction in the cost per item price for three drugs, as lower-cost generic formulations became available (Anastrozole, Exemestane and Letrozole). These are mainly used in primary care; therefore there was not the comparable reduction in secondary care costs. Sources: 1. Prescribing Analysis and CosT tool (PACT) system. The Health and Social Care Information Centre, Prescribing and Primary Care Services. 2. IMS data. Hospital Pharmacy Audit. Some supplies through homecare providers may not be captured, therefore cost estimates may be under-stated. | |||
Corrected as per Written Statement, 3rd September 2013